Pipeline: New therapies to come for debilitating eye diseases

Article

New drug from Gensight Biologics hits pipeline

GenSight Biologics has developed a therapy for Leber hereditary optic neuropathy (LHON), called Lumevoq. The drug has been submitted for approval in Europe, and the company plans to submit for U.S. Food & Drug Administration approval in late 2021.

Dr. Gilly explains the mechanism of action for Lumevoq and provides a look into the GenSight Biologics pipeline for the future.

Related: Myopia control data and whats to come with Dr. Noel Brennan

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Subscribe Now!
Recent Videos
Karl Stonecipher ASCRS 2025
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
At ASCRS 2025, Alex Hacopian, MD, shares information from his presentation on next-gen presbyopia-correcting intraocular lenses.
Eva Kim, MD, shares visual outcomes of EVO implantable collamer lens in patients with low to moderate myopia.
Related Content
Doctor conducting eye exam on patient Image credit: AdobeStock/NDABCREATIVITY

What to keep in mind when diagnosing and treating glaucoma

Benjamin P. Casella, OD, FAAO
May 12th 2025
Article
You and Eye by Optometry Times with host Miriam Korik, OD

You and Eye: Myopia cannot be viewed as a specialty in today's practice setting

Miriam Korik, OD;Justin Kwan, OD, FAAO;Emily Kaiser Maharjan, Assistant Managing Editor
October 18th 2024
Podcast
Woman consoling her friend on a park bench AdobeStock/MonkeyBusiness

What do you say when your best friend asks for dry eye advice?

Katherine M. Mastrota, MS, OD, FAAO, Dipl ABO
May 8th 2025
Article
You and Eye: Mastering myopia management - with Justin Kwan, OD, FAAO

You and Eye: Mastering myopia management - with Justin Kwan, OD, FAAO

Miriam Korik, OD;Justin Kwan, OD, FAAO;Emily Kaiser Maharjan, Assistant Managing Editor
October 9th 2024
Podcast
Child applying contact lens to eye Image credit: AdobeStock/zulfiska

New study supports retention of myopia control in CooperVision's MiSight 1 day contact lenses

Jordana Joy, Associate Editor
May 6th 2025
Article
New data for reproxalap for dry eye disease meets primary end point, Aldeyra Therapeutics says. ©megaflopp—stock.adobe.com

Aldeyra Therapeutics hits primary end point in 1 of 2 phase 3 trials for reproxalap

Emily Kaiser Maharjan, Assistant Managing Editor
May 6th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.